Iteos Therapeutics Stock Investor Sentiment
| ITOS Stock | USD 10.13 0.01 0.1% |
Slightly above 63% of Iteos Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Iteos Therapeutics suggests that many traders are alarmed. Iteos Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Iteos Therapeutics' earnings reports, geopolitical events, and overall market trends.
Comfort Level 37
Alarmed
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Iteos Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Iteos Therapeutics.
News SentimentNeutral | Hype SentimentNeutral | Insider SentimentDisposing |
Iteos Historical Sentiment
Although Iteos Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Iteos, such as negative comments on social media and news outlets, may cause fear in the market and push Iteos Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Iteos.
Iteos Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Iteos Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Iteos Therapeutics Historical Investor Sentiment
Investor biases related to Iteos Therapeutics' public news can be used to forecast risks associated with an investment in Iteos. The trend in average sentiment can be used to explain how an investor holding Iteos can time the market purely based on public headlines and social activities around Iteos Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Iteos Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Iteos Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Iteos Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Iteos Therapeutics.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Iteos Therapeutics' Stock prices. Below is the latest headlines and news related to Iteos Therapeutics Stock. Current markets are strongly bullish. About 79% of major world exchanges and indexes are currently up. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Iteos Therapeutics that are available to investors today. This information is accessible both publicly - through Iteos Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Iteos-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Iteos Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Iteos Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Iteos Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Iteos Therapeutics alpha.
Iteos Largest EPS Surprises
Earnings surprises can significantly impact Iteos Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-10 | 2022-09-30 | 0.1 | 0.03 | -0.07 | 70 | ||
2021-05-13 | 2021-03-31 | -0.48 | -0.39 | 0.09 | 18 | ||
2025-05-08 | 2025-03-31 | -0.9035 | -0.8 | 0.1035 | 11 | ||
2020-11-12 | 2020-09-30 | -0.36 | -0.48 | -0.12 | 33 | ||
2024-11-05 | 2024-09-30 | -0.89 | -1.0515 | -0.1615 | 18 | ||
2024-03-06 | 2023-12-31 | -1.03 | -0.85 | 0.18 | 17 |
There is far too much social signal, news, headlines, and media speculation about Iteos Therapeutics that are available to investors today. This information is accessible both publicly - through Iteos Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Iteos-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Iteos Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Iteos Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Iteos Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Iteos Therapeutics alpha.
Iteos Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Insider Trading | 05/13/2025 |
2 | GSK Inks 2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug | 05/15/2025 |
3 | iTeos Therapeutics Announces Its Intention to Wind Down Operations | 05/28/2025 |
4 | Wedbush Lowers Earnings Estimates for iTeos Therapeutics | 05/30/2025 |
5 | Disposition of 38227 shares by Hallal David of Iteos Therapeutics at 10.07 subject to Rule 16b-3 | 06/04/2025 |
6 | Disposition of 38227 shares by Hallal David of Iteos Therapeutics at 10.15 subject to Rule 16b-3 | 06/05/2025 |
7 | Disposition of 38228 shares by Hallal David of Iteos Therapeutics at 4.3 subject to Rule 16b-3 | 06/06/2025 |
8 | Disposition of 43883 shares by Michel Detheux of Iteos Therapeutics at 10.02 subject to Rule 16b-3 | 06/10/2025 |
9 | iTeos Therapeutics Holds Annual Stockholders Meeting - TipRanks | 06/17/2025 |
10 | iTeos Therapeutics An Example of Biotech Liquidations | 07/08/2025 |
11 | HAREHOLDER ALERT The MA Class Action Firm Announces An Investigation of iTeos Therapeutics, Inc. | 07/21/2025 |
12 | SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates ITOS, ZIMV, TASK, OLO on Behalf of Shareholders | 07/23/2025 |
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.